Q2 2026 results exceeded expectations, with revenues of $71.7B and adjusted EPS of $7.78. Full-year adjusted EPS outlook was raised to at least $30.45, driven by strong specialty growth, biosimilar adoption, and disciplined execution across segments.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.